Blocking the CXCL12/CXCR4 pathway may suppress the growth of breast cancer cells by reducing the expression of proteins that facilitate the G2-M phase transition (PLK1, Myt1, and cyclin B1), and then disrupting mitotic processes (34). Here, PLK1 is linked to breast carcinoma.